Effects of HIV status and other variables on the outcome of tuberculosis treatment in Spain;Efectos del VIH y otras variables sobre el resultado del tratamiento antituberculoso en España

Archivos de Bronconeumologia

Volumn 41, Issue 7, 2005, Pages 363-370

  Diez Ruiz Navarro M ^a,b   Hernandez Espinosa J A ^a   Bleda Hernandez M J ^a   Diaz Franco A ^a   Castells Carrillo, C ^a   Dominguez Garcia A ^a   Garcia Fulgueiras A M ^a   Gayoso Diz, P ^a   Lopez De Valdivielso M J ^a   Vazquez Fernandez M F ^a  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

HIV status; Outcome of tuberculosis treatment; Potentially unsatisfactory outcome

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; NEWBORN; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SCHOOL CHILD; SPAIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 23044484736     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076965     Document Type: Article

References (32)

1. World Health Organization. WHO Tuberculosis Program:Framework for effective tuberculosis control. Ginebra: WHO; 1994, WHO/TB/94. p. 179.
2. Veen J, Raviglione M, Rieder H, Migliori G, Graf P, et al. Standardised tuberculosis treatment outcome monitoring in Europe-Recommendations of a Working Group of the World Health Organization and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J. 1998;12:505-10.
3. EuroTB (INVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis case notified in 2001. 2003. p. 1-120.
4. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe. Mid-year report 2002. Saint-Maurice: Institut de Veille Sanitaire, 2002 [report n.° 67].
5. Castilla Catalán J, Guerra Romero L, Cañón Campos J, Noguer Zambrano I, Parras Vázquez F. Descenso de la incidencia de tuberculosis siguiendo la introducción de los nuevos tratamientos frente al VIH. Rev Clin Esp. 1999;199:76-7.
6. Díez M, Huerta C, Moreno T, Caloto T, Guerra D, Pozo F, et al. Tuberculosis in Spain: epidemiological pattern and clinical practice. Int J Tuberc Lung Dis. 2002;6:295-300.
7. Vall Mayans M, Maguire A, Miret M, Alcaide J, Parron I, Casabona J. The spread of AIDS and the re-emergence of tuberculosis in Catalonia, Spain. AIDS. 1997;1:499-505.
8. Díez Ruiz-Navarro M, Hernández Espinosa J, Caloto González T, Castells Carillo C, Domínguez García A, García Fulgueiras A, et al. Resultados del tratamiento antituberculoso en seis comunidades autónomas españolas. Med Clin (Barc). 2001;117:474-80.
9. nd ed. New York: Wiley-Intersciencie; 2000.
10. StataCorp. Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation; 1999.
11. Zellweger J, Coulon P. Outcome of patients treated for tuberculosis in Vaud County, Switzerland. Int J Tuberc Lung Dis. 1998;2(5):372-7.
12. Grupo de Trabajo del PMIT/Grupo de trabajo del PMETA. La tuberculosis en Andalucía. Resultados de los Proyectos Multicéntricos PMITA-PMETA. Sevilla: Junta de Andalucía, Consejeria de Salud; 2000.
13. Galdós Tangüis H, Caylà J, García de Olalla P, Jansà J, Brugal T. Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in Barcelona (1987-1996). Int J Tuberc Lung Dis. 2000;4(1):55-60.
14. Campos Rodríguez F, Muñoz Lucena F, Umbría Domínguez S, Méndez C, Nogales Pérez M. Resultados del tratamiento de la tuberculosis inicial en el área sur de Sevilla en un período de 5 años (1994-1998). Arch Bronconeumol. 2001;37:177-83.
15. Blanco-Aparicio M, Fernández E, Anibarro L, Vázquez E, Lema R, Penas A, et al. Follow-up of tuberculosis cases diagnosed in Galicia, Spain in 1995. Int J Tuberc Lung Dis. 1997;1(5):S73.
16. Chaisson R, Clermont H, Holt E, Cantave M, Johnson M, Atkinson J, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996;154:1034-8.
17. Murray J, Sonnenberg P, Stuart C, Shearer C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159(3):733-40.
18. Wobeser W, Yuan L, Naus M. Outcome of pulmonary tuberculosis treatment in the tertiary care setting-Toronto 1992/93. Tuberculosis Treatment Completion Study Group. CMAJ. 1999;160:789-94.
19. Rodger A, Toole M, Lalnuntluangi B, Muana V, Deutschmann P. DOTS-based tuberculosis treatment and control during civil conflict and an HIV epidemic, Churachandpur District, India. Bull WHO 2002;80:451-6.
20. El-Sadr W, Perlman D, Denning E, Matts J, Cohn D. A review of efficacy studies of a 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis. 2001;32(4):623-32.
21. Ministerio de Sanidad y Consumo. Fondo de Investigación Sanitaria. Consenso Nacional para el Control de la Tuberculosis en España. Med Clin (Barc). 1992;98:24-31.
22. WHO. Global Tuberculosis Programme. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance 1994-1997. Geneva: WHO; 1997 [Document WHO/TB/97.229].
23. Martín-Casabona N, Alcaide F, Coll P, González J, Manterola J, Saldo M, et al. Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc). 2000;115:493-81.
24. Torres L, Arazo P, Blas Pérez J, Amador MP, Lezcano MA, Revillo MJ, et al. Resistencias de Mvcobacteriuin tuberculosis en Zaragoza (1993-1997) y factures asociados. Med Clin (Barc). 2000;115:605-9.
25. Diez M, Bleda M, Camafort M, Cepeda C, Costa A, Ferrero O, et al. Occurrence of tuberculosis and latent tuberculosis infection among HIV-positive subjects in Spain. Int J Tuberc Lung Dis. 2002;6 Suppl 1:90.
26. Del Amo J, Del Romero J, Barrasa A, Pérez-Hoyos S, Rodríguez C, Díez M, et al. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect. 2002;78:255-60.
27. Pérez-Hoyos S, Del Amo J, Muga R, Del Romero J, García de Olalla P, Guerrero R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS. 2003;17:1-7.
28. Alwood K, Keruly J, Moore-Rice K, Stanton D, Chaulk C, Chaisson R. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS. 1994;8:1103-8.
29. Snyder D, Paz E, Mohle-Boetani J, Fallstad R, Black R, Chin D. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999; 160(1):178-85.
30. Marco A, Caylà J, Serra M, Pedro R, Sanrama C, Guerrero R, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12:967-71.
31. Kirk O, Gatell J, Mocroft A, Pedersen C, Proenca R, Brettle R, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med. 2000;162:865-72.
32. Dean G, Edwards S, Ives N, Matthews G, Fox E, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.